Core Viewpoint - Nanjing Pharmaceutical plans to invest 120 million yuan in a new investment company focused on the medical device sector, specifically targeting a stake in Ningbo Jiangfeng Biological Information Technology Co., Ltd. [1][2] Group 1: Investment Details - Nanjing Pharmaceutical will hold a 59.9% stake in the newly established Nanjing XG South Medicine Medical Device Investment Company, which will focus on acquiring approximately 22.5% of Jiangfeng Biological at a valuation not exceeding 750 million yuan [1][2] - The investment aligns with Nanjing's municipal strategy to enhance industrial strength and integrate resources within the "2+6+6" innovative industrial system [2] Group 2: Strategic Alignment - The establishment of the investment fund is part of Nanjing Pharmaceutical's "14th Five-Year" strategic plan, which emphasizes the integration of health industry development and digital transformation [2] - The investment is expected to enhance the company's core competitiveness while extending its existing industrial chain [2] Group 3: Target Company Overview - Jiangfeng Biological has over a decade of experience in the digital pathology sector and is recognized as a national high-tech enterprise [3] - The company offers a comprehensive range of products and services, including digital pathology scanning systems and AI-assisted diagnostic systems, positioning it as a leader in the industry [3] - Jiangfeng's strong R&D capabilities and established market presence are expected to complement Nanjing Pharmaceutical's extensive business network and supply chain [3]